Key result
Percutaneous Sapien XT valve-in-valve implantation in the tricuspid position was feasible in two young male patients with congenital heart disease.
Why the study?
Is percutaneous Sapien XT valve-in-valve implantation feasible in the tricuspid position for patients with congenital heart disease?
Case Report (n=2)
Is percutaneous Sapien XT valve-in-valve implantation feasible in the tricuspid position for patients with congenital heart disease?
Percutaneous Sapien XT valve-in-valve implantation in the tricuspid position is feasible and may reduce the need for repeated open-heart surgeries in patients with congenital heart disease.
Supports feasibility in select congenital cases; leaves open durability, safety, and need for prospective trials before wider use.
We present two cases of percutaneous Sapien XT valve-in-valve implantation in the tricuspid position: a 20-year-old man with severe congenital pulmonary stenosis and percutaneous valvuloplasty, who required surgical implantation of two protheses, pulmonary and tricuspid, and a 12-year-old boy with CHD and a degenerated tricuspid prosthesis. We implanted three Sapien XT valve-in-valves, two in the tricuspid position and one in the pulmonic position. Sapien XT valve-in-valve implantation in the tricuspid position is feasible and can decrease the number of surgeries in CHD patients.
No takes yet. Share an insight, caveat, or question.
Álvarez-Fuente et al. (2017) conducted a case report in Congenital heart disease with degenerated tricuspid prosthesis (n=2). Percutaneous Sapien XT valve-in-valve implantation was evaluated on Feasibility of implantation. Percutaneous Sapien XT valve-in-valve implantation in the tricuspid position was feasible in two young male patients with congenital heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: